Cat. No. 1018
Chemical Name: 2-[2-(5-Bromo-1H-indol-3-yl)ethyl]-
Biological ActivityPotent CCK2 receptor antagonist (IC50 = 9.3 nM for inhibition of 125I-labeled CCK-8 sulfate binding at mouse brain membranes).
Licensing InformationSold with the permission of Eli Lilly and Company.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Suman-Chauhan et al (1996) The influence of guanyl nucleotide on agonist and antagonist affinity at guinea-pig CCK-B / gastrin receptors: binding studies using [3H]PD140376. Regul.Pept. 65 37. PMID: 8876034.
Yu et al (1991) Quinazolinone cholecystokinin receptor ligands. J.Med.Chem. 34 1505. PMID: 2016728.
If you know of a relevant reference for LY 225910 please let us know.
Citations are publications that use Tocris products. Selected citations for LY 225910 include:
Seillier et al (2013) Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia. Neuropharmacology 38 1816. PMID: 23563893.
Karson et al (2008) Cholecystokinin inhibits endocannabinoid-sensitive hippocampal IPSPs and stimulates others. J Card Fail 54 117. PMID: 17689570.
Gallopin et al (2006) Cortical sources of CRF, NKB, and CCK and their effects on pyramidal cells in the neocortex. Neuropsychopharmacology 16 1440. PMID: 16339088.
Do you know of a great paper that uses LY 225910 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: LY 225910, supplier, Potent, CCK2, antagonists, Cholecystokinin2, Receptors, LY225910, Tocris Bioscience, CCK2 Receptor Antagonist products